Coloplast A/S (GB:0QBO)

LSE:0QBO

0QBO

Coloplast A/S

RESEARCH TOOLSreports

Coloplast A/S (0QBO) Share Forecast & Price Target

43 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QBO Analyst Ratings

Hold

2 Buy

1 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Coloplast

A/S

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QBO Stock 12 Month Forecast

Average Price Target

kr486.75

▼(-16.66% Downside)

Based on 4 Wall Street analysts offering 12 month price targets for Coloplast A/S in the last 3 months. The average price target is kr486.75 with a high forecast of kr530.00 and a low forecast of kr435.00. The average price target represents a -16.66% change from the last price of kr584.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"381":"kr381","436":"kr436","491":"kr491","546":"kr546","601":"kr601"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":530,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr530.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":486.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr486.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr435.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[381,436,491,546,601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,382,393.38461538461536,404.7692307692308,416.15384615384613,427.53846153846155,438.9230769230769,450.3076923076923,461.6923076923077,473.0769230769231,484.46153846153845,495.84615384615387,507.2307692307692,518.6153846153846,{"y":530,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,382,390.0576923076923,398.11538461538464,406.1730769230769,414.2307692307692,422.28846153846155,430.34615384615387,438.4038461538462,446.46153846153845,454.5192307692308,462.5769230769231,470.63461538461536,478.69230769230774,{"y":486.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,382,386.0769230769231,390.15384615384613,394.2307692307692,398.3076923076923,402.38461538461536,406.46153846153845,410.53846153846155,414.61538461538464,418.6923076923077,422.7692307692308,426.8461538461538,430.9230769230769,{"y":435,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":600.4,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":566.499,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":567.097,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.326,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":531.175,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":561.798,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":561.052,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":537.399,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":529.905,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":479.193,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":441.097,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":394.952,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":382,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr530.00

Average Price Targetkr486.75

Lowest Price Targetkr435.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graham Doyle

UBS

kr530

Buy

-9.25%

Downside

Reiterated

05/21/26

Coloplast A/S (0QBO) Receives a Buy from UBS

Christophe dombu

Kepler Capital

kr482

Buy

-17.47%

Downside

Initiated

05/20/26

Coloplast A/S (0QBO) Receives a New Rating from Kepler Capital

Hassan Al-Wakeel

Barclays

kr540→kr500

Hold

-14.39%

Downside

Reiterated

04/26/26

Coloplast A/S (0QBO) Receives a Hold from Barclays

Richard Felton

Goldman Sachs

kr435

Sell

-25.52%

Downside

Downgraded

04/07/26

Coloplast A/S (0QBO) was downgraded to a Sell Rating at Goldman Sachs

Susannah Ludwig

Bernstein

kr555

Hold

-4.97%

Downside

Initiated

01/28/26

Bernstein Initiates a Hold Rating on Coloplast A/S (0QBO)

Aisyah Noor

Morgan Stanley

kr535→kr541

Sell

-7.37%

Downside

Reiterated

12/15/25

Morgan Stanley Sticks to Its Sell Rating for Coloplast A/S (0QBO)

Falko Friedrichs

Deutsche Bank

kr708→kr660

Hold

13.00%

Upside

Reiterated

09/08/25

Deutsche Bank Keeps Their Hold Rating on Coloplast A/S (0QBO)

Sam England

Berenberg Bank

kr700→kr650

Hold

11.29%

Upside

Reiterated

09/05/25

Coloplast A/S (0QBO) Gets a Hold from Berenberg Bank

Jack Reynolds-Clark

RBC Capital

kr700→kr710

Hold

21.56%

Upside

Reiterated

08/22/25

RBC Capital Remains a Hold on Coloplast A/S (0QBO)

Julien Dormois

Jefferies

kr850→kr800

Buy

36.97%

Upside

Reiterated

08/20/25

Jefferies Keeps Their Buy Rating on Coloplast A/S (0QBO)

Unknown Analyst

Jyske Bank

Not Ranked

Jyske Bank

kr750

Buy

28.41%

Upside

Upgraded

07/08/25

Positive Report for Coloplast A/S (0QBO) from Jyske Bank

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graham Doyle

UBS

kr530

Buy

-9.25%

Downside

Reiterated

05/21/26

Coloplast A/S (0QBO) Receives a Buy from UBS

Christophe dombu

Kepler Capital

kr482

Buy

-17.47%

Downside

Initiated

05/20/26

Coloplast A/S (0QBO) Receives a New Rating from Kepler Capital

Hassan Al-Wakeel

Barclays

kr540→kr500

Hold

-14.39%

Downside

Reiterated

04/26/26

Coloplast A/S (0QBO) Receives a Hold from Barclays

Richard Felton

Goldman Sachs

kr435

Sell

-25.52%

Downside

Downgraded

04/07/26

Coloplast A/S (0QBO) was downgraded to a Sell Rating at Goldman Sachs

Susannah Ludwig

Bernstein

kr555

Hold

-4.97%

Downside

Initiated

01/28/26

Bernstein Initiates a Hold Rating on Coloplast A/S (0QBO)

Aisyah Noor

Morgan Stanley

kr535→kr541

Sell

-7.37%

Downside

Reiterated

12/15/25

Morgan Stanley Sticks to Its Sell Rating for Coloplast A/S (0QBO)

Falko Friedrichs

Deutsche Bank

kr708→kr660

Hold

13.00%

Upside

Reiterated

09/08/25

Deutsche Bank Keeps Their Hold Rating on Coloplast A/S (0QBO)

Sam England

Berenberg Bank

kr700→kr650

Hold

11.29%

Upside

Reiterated

09/05/25

Coloplast A/S (0QBO) Gets a Hold from Berenberg Bank

Jack Reynolds-Clark

RBC Capital

kr700→kr710

Hold

21.56%

Upside

Reiterated

08/22/25

RBC Capital Remains a Hold on Coloplast A/S (0QBO)

Julien Dormois

Jefferies

kr850→kr800

Buy

36.97%

Upside

Reiterated

08/20/25

Jefferies Keeps Their Buy Rating on Coloplast A/S (0QBO)

Unknown Analyst

Jyske Bank

Not Ranked

Jyske Bank

kr750

Buy

28.41%

Upside

Upgraded

07/08/25

Positive Report for Coloplast A/S (0QBO) from Jyske Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Coloplast A/S

3 Months

Aisyah NoorMorgan Stanley

Success Rate

8/9 ratings generated profit

Average Return

+7.86%

Copying Aisyah Noor's trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +7.86% per trade.

1 Year

Aisyah NoorMorgan Stanley

Success Rate

9/9 ratings generated profit

Average Return

+32.38%

Copying Aisyah Noor's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.38% per trade.

2 Years

Aisyah NoorMorgan Stanley

Success Rate

9/9 ratings generated profit

Average Return

+38.46%

Copying Aisyah Noor's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +38.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QBO Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QBO has received 2 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 0QBO average Analyst price target in the past 3 months is 486.75.

Each month's total comprises the sum of three months' worth of ratings.

0QBO Financial Forecast

0QBO Earnings Forecast

Next quarter’s earnings estimate for 0QBO is kr6.23 with a range of kr5.81 to kr6.50. The previous quarter’s EPS was kr6.16. 0QBO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0QBO has Performed in-line its overall industry.

0QBO Sales Forecast

Next quarter’s sales forecast for 0QBO is kr7.25B with a range of kr7.18B to kr7.33B. The previous quarter’s sales results were kr7.08B. 0QBO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0QBO has Performed in-line its overall industry.

0QBO Stock Forecast FAQ

What is GB:0QBO’s average 12-month price target, according to analysts?

Based on analyst ratings, Coloplast A/S’s 12-month average price target is 486.75.

What is GB:0QBO’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0QBO, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Coloplast A/S a Buy, Sell or Hold?

Coloplast A/S has a consensus rating of Hold, which is based on 2 buy ratings, 1 hold ratings and 1 sell ratings.

What is Coloplast A/S’s share price target?

The average share price target for Coloplast A/S is 486.75. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr530.00 ,and the lowest forecast is kr435.00. The average share price target represents -16.66% Decrease from the current price of kr584.05.

What do analysts say about Coloplast A/S?

Coloplast A/S’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Coloplast A/S?

To buy shares of GB:0QBO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Coloplast A/S (0QBO) Share Forecast & Price Target

0QBO Analyst Ratings

0QBO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Coloplast A/S

0QBO Analyst Recommendation Trends

0QBO Financial Forecast

0QBO Earnings Forecast

0QBO Sales Forecast

0QBO Stock Forecast FAQ

Detailed List of Analyst Forecasts